Company Overview and News
Wall Street expects a year-over-year increase in earnings on higher revenues when Range Resources (RRC - Free Report) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
RRC RGRYY WNEB RRL RRS RGRLF
Range Resources Corporation (RRC - Free Report) has inked an agreement to divest a proportionately reduced 1% overriding royalty in Washington County, Pennsylvania leases. The transaction is expected to raise gross proceeds of $300 million. The company’s Washington County assets include about 300,000 net surface acres that produced 1.7 billion cubic feet equivalent (Bcfe) net per day in the second quarter of 2018.
RRC RGRYY SHLX CTRL RRL RRS RGRLF PSXP
Chicago, IL – October 16, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chesapeake Energy Corp. (CHK - Free Report) , Comstock Resources, Inc. (CRK - Free Report) , Southwestern Energy Company (SWN - Free Report) , Range Resources Corp.
JAZZ DLTH CHKVP CRK RRL CTRL CHKDH CHKVZ CHKDG SHEN CHKDJ CHKDP AB CKRGZ CNX.WI BVX RRS RGRLF CHKWZ RRC MFC 0945 RGRYY CHK CHK.WI PATK MFC
FORT WORTH, Texas, Oct. 15, 2018 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced that it has signed and closed on an agreement to sell a proportionately reduced 1% overriding royalty in its Washington County, Pennsylvania leases for gross proceeds of $300 million.
RRC RGRYY RRL RRS RGRLF
The U.S. Energy Department's weekly inventory release showed a natural gas storage injection that fell in line with market expectations. Meanwhile, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ CNX.WI CHKVP CRK RRL RRS CHKDH CHKVZ RGRLF CHKDG CHKWZ RRC CHKDJ CHKDP RGRYY CHK CHK.WI GPOR
Larger and more financially healthy E&P companies are grouped together for analysis purposes in this "Tier One Producer" or "TOP Club"
CRC GDPMQ CHKVP PSX CRK QEP CHKVZ CRZO GDAOQ EGC EXXIQ SNZYP GDRRQ AMPY TALO SRCI EEXXQ BCEI RRS JONE WPX ESTE EXXI GDP CHK SGY TTEN MPOYQ SDRXP LINE SDRXQ APA HES DVN PVA EPE PIONF CHKDH CHKDG MCF CHKDJ ROSEU VNR CHKDP REI RSPP JNEEP AMR AMGP JAG ROSE LINEQ CKRGZ EVEP EOG RGRYY UPLMQ VNRCP PIO LNGG AR SWTF AM EXIXQ CHAP VNRBP SN XOG NBL WLL PDCE SM CTLR HKRCP SD RGRLF RRC DNR MPO VNRAP CLR GDPAN GDPAQ ECR CHPE UPL WPXP SDRPQ REN PE CXO RRL SCAZP AXAS COP AREX ECA SFY EVEPQ CDEV BRMR GDPM PVAYQ VNRR ECA SBOW CHKWZ GDUEQ SDOCQ GDANQ CHK.WI PVAC LPI WES HK HPR BRY
Healthier oil and natural gas prices have made the Energy sector an attractive investment opportunity. Our latest Earnings Trends shows that Energy will lead all Zacks Sectors to witness the strongest earnings growth in Q3.
CBSH CBSHP WLL HES RRL RRS CBCB RGRLF COP RRC RGRYY OXY
Investors in Range Resources Corporation (RRC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 12, 2018 $18.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
RRC CBSH RGRYY CBSHP RRL RRS CBCB SGH RGRLF
2018-10-11 zacks - 1
Chicago, IL –October 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , Range Resources Corp. (RRC - Free Report) , Penn Virginia Corp. (PVAC - Free Report) , Shell Midstream Partners, L.
STZ.B BLT BHPBF PVAYQ UNT PVA RRL STZ RRS RGRLF RRC RGRYY BHP SHLX CVX PVAC BBL BHP URBN BHPLF
Eni SpA (E - Free Report) inked a Letter of Intent (LOI) with National Oil Corporation (NOC) and BP plc (BP - Free Report) . Per the agreement, the company will be able to acquire a stake of 42.5% in BP’s Exploration and Production Sharing Agreement (“EPSA”) in Libya. The agreement also involves Eni’s acquisition of the operatorship, currently held by BP, in the contractual areas A and B (onshore) as well as C (offshore) in Libya.
RRC RGRYY RRL RRS RGRLF
Chicago, IL – October 9, 2018 - Stocks in this week’s article are Range Resources Corporation (RRC - Free Report) , lululemon athletica inc. (LULU - Free Report) , North American Construction Group Ltd. (NOA - Free Report) , ChannelAdvisor Corporation (ECOM - Free Report) and Southwest Gas Holdings, Inc. (SWX - Free Report) .
SWX GFN GFNCP VTNR LBTY FNLC RRL CLH LBTYK LILAB FBLV LULU FBP LBTYB LBTYA RRS RGRLF GFNSL RRC BRK.A ECOM RGRYY LILAK FBPRM FBNC FBPRL GFDV FBPRO FBPRN FBPRP LILA
Investment strategies are formed on thorough research and in-depth understanding of industries. However, the general belief is that only risky stocks turn out to be profitable investments. Notably, risky portfolios only prove rewarding when the market is bullish.
SWX RRC ECOM RGRYY LULU RRL RRS RGRLF
SCANA Corporation (SCG - Free Report) and Dominion Energy Inc (D - Free Report) have reached an agreement with Public Staff of the North Carolina Utilities Commission (NCUC) to ensure constancy in rates for customers as well as services for one of the company’s gas utilities. The stipulation agreement with NCUC staff and an intervenor focuses on PSNC Energy, a natural gas utility based in Gastonia, NC.
RRC RGRYY SCG SCU RRL RRS RGRLF
2018-10-08 seekingalpha - 5
E&P companies that are neither top institutional favorites nor companies I would classify in my Bottom of the Barrel Club may have wide appeal to investors.
GIS XOM PXD QEP AR CRZO WMB XOG NBL WLL PDCE SRCI SM CTLR NFX RRS WPX ESTE RGRLF RRC WTI CLR OXY AEUA HAL APC APA WPXP DVN CXO PE RRL COP ROSEU RSPP REI AMR EGN JAG ROSE CDEV D COG EOG RGRYY HP CVX LPI HK FANG
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:RRL / RANGE RESOURCES on message board site Silicon Investor.